Durham-based Mycovia Pharmaceuticals, formerly Viamet Pharmaceuticals, has begun two Phase 3 clinical trials of its lead drug candidate for treating recurrent yeast infections in women. The trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback